Dr. Kulkarni, who became chancellor of Penn State in 2010, is also a professor of finance, and specializes in the areas of capital budgeting, capital structure and information content of stock prices.
Prior to becoming chancellor, he was senior associate dean for academic affairs from 2006 to 2010.
"Dr. Kulkarni's strategic vision, his grasp of expansive growth, and his knowledge of capital structuring will be valuable toNanoViricides as we move further towards drug approvals," said NanoViricides' president Anil R. Diwan.
According to the company statement, Dr. Kulkarni oversaw enrollment growth at Penn State as well as the introduction of new degree programs and expanded international outreach efforts. He is also an invited lecturer and consultant to several academic institutions in the U.S. and abroad, as well as to state government and non-profit organizations.
"Dr. Kulkarni's strong integrity and professional expertise will be of great help in strengthening our corporate governance as well as help us with corporate growth planning and execution," said CEO of NanoViricides in the release, Eugene Seymour.
NanoViricides currently has six drug candidates in its pipeline and is working to advance both an injectable and an oral anti-flu drug. The company is now preparing for toxicology studies for its first FluCide candidate, expected to be wrapped up before the middle of next year.
The drug candidate has the potential to wipe out virtually all strains of the pesky influenza A virus, including the recent H7N9 avian strain that has been plaguing China.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.